Everything below concerns pentadecapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | computed for the free peptide |
| Molecular weight | about 1419 Da | monoisotopic mass near 1418.7 |
| Amino acid count | 15 | single chain, no disulfide bonds |
| Solubility | freely soluble in water | also dissolves in saline and phosphate buffer |
| Common synonyms | pentadecapeptide BPC, BPC 157 | fragment notation varies by source |
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
The polymerization of one kind of monomer gives a homopolymer. Many polymers are copolymers, meaning that they are derived from two different monomers. In the case of condensation polymerizations, the ratio of comonomers is usually 1:1. For example, the formation of many nylons requires equal amounts of a dicarboxylic acid and diamine. In the case of addition polymerizations, the comonomer content is often only a few percent. For example, small amounts of 1-octene monomer are copolymerized with ethylene to give specialized polyethylene.
In clinical trials, refers to a drug (including a new drug, dose, combination, or route of administration) or procedure that has undergone basic laboratory testing and received approval from the U.S. Food and Drug Administration (FDA) to be tested in human subjects. A drug or procedure may be approved by the FDA for use in one disease or condition, but be considered experimental in other diseases or conditions. Also called investigational. (NCI) Experimental drug
The soybean, soy bean, or soya bean (Glycine max) is a species of legume native to East Asia, widely grown for its edible bean. Soy is a staple crop, the world's most grown legume, and an important animal feed. Soy is a key food source, owing to its high protein and oil content. Soybean oil is widely used in cooking, as well as in industry. Traditional unfermented food uses of soybeans include edamame, as well as soy milk, from which tofu and tofu skin are made. Fermented soy foods include soy sauce, fermented bean paste, nattō, and tempeh. Fat-free (defatted) soybean meal is a significant and cheap source of protein for animal feeds and many packaged meals. For example, soybean products, such as textured vegetable protein (TVP), are ingredients in many meat and dairy substitutes. Soy-based foods are traditionally associated with East Asian cuisines, and still constitute a major part of East Asian diets, but processed soy products are increasingly used in Western cuisines. Soy was domesticated from the wild soybean (Glycine soja) in north-central China between 6,000 and 9,000 years ago. Brazil and the United States lead the world in modern soy production. The majority of soybeans are genetically modified, usually for either insect, herbicide, or drought resistance. Three-quarters of soy is used to feed livestock, which in turn go to feed humans. Increasing demand for meat has substantially increased soy production since the 1980s, and contributed to deforestation in the Amazon. Soybeans contain significant amounts of phytic acid, dietary minerals, and B vitamins.
== Career == Upon his return to Los Angeles, a childhood friend (88rising artist August 08) brought him along to studio sessions, where he rose to making beats for Duckwrth, Wale, Kehlani and others. In 2018 "Controller" received airplay on BBC Radio 1, and an Essential New Tune call-out from Pete Tong. Australian radio station Triple J added "Controller" to their A-list rotation and called it "one of 2018's biggest cult hits." Channel Tres continued to see success with the release of his self-titled EP in 2018 and further singles, including his single "Black Moses", which featured JPEGMAFIA. He played his first headline shows in the US in 2019.
He announced the construction of seventeen "large schools" in different regions of the country, intended to offer high-quality education and modern equipment, seeking to reduce school dropout and improve learning indicators. Peña expressed enthusiasm for this project and acknowledged that there were still challenges to overcome in the national education system. In March 2025, the president highlighted the historic delivery of 430,000 school furniture items as part of the strengthening of the education system and the improvement of learning conditions. He announced the expansion of places for government scholarships, benefiting more students who passed the tests and met the established requirements.
Sources: en.wikipedia.org
The two were together for eight months between 2015 and 2016. Kardashian began dating basketball player Tristan Thompson in 2016. Kardashian gave birth to a daughter, True Thompson, on April 12, 2018, amidst controversy after Thompson was found to have cheated on Kardashian during her pregnancy. In February 2019, Kardashian and Thompson split after it was revealed that Thompson had allegedly cheated on Kardashian with her younger half-sister Kylie Jenner's then-best friend Jordyn Woods. After quarantining together during the COVID-19 pandemic for the sake of their daughter, they ended up rekindling their relationship in August 2020. They became engaged in February 2021, but split for good in December 2021, when it was revealed that Thompson had cheated on Kardashian again in March 2021, and fathered a son who was born in December 2021. In July 2022, it was announced that Kardashian and Thompson were expecting a baby boy via surrogacy, who was conceived before Kardashian discovered Thompson's cheating. Their son, Tatum, was born on July 28, 2022.
=== Oncology === Keytruda (pembrolizumab) ($29.5 billion in 2024 revenues) is an immune modulator for the treatment of cancer. Lynparza (olaparib) ($1.3 billion in 2024 revenues) is a PARP inhibitor used to treat BRCA-mutated advanced ovarian cancer. Lenvima (lenvatinib) ($1.0 billion in 2024 revenues) is used for the treatment of thyroid cancer. Welireg (Belzutifan) ($0.5 billion in 2024 revenues) is used for the treatment of von Hippel–Lindau disease-associated renal cell carcinoma. Reblozyl (Luspatercept) ($0.4 billion in 2024 revenues) is used for the treatment of anemia in beta thalassemia and myelodysplastic syndromes.
=== Non-canonical phosphorylation on His, Asp, Cys, Glu, Arg and Lys in human cells === Widespread human protein phosphorylation occurs on multiple non-canonical amino acids, including motifs containing phosphorylated histidine (1 and 3 positions), aspartate, cysteine, glutamate, arginine, and lysine in HeLa cell extracts. Due to the chemical and thermal lability of these phosphorylated residues, special procedures and separation techniques are required for preservation alongside the heat stable 'classical' Ser, Thr and Tyr phosphorylation.
Bill 28 imposes a contract on CUPE, and makes it illegal to strike, setting fines of $4000 for workers. The bill invokes the notwithstanding clause, shielding it from being struck down by the courts by allowing the bill to operate despite the right to collective bargaining granted by the Canadian Charter of Rights and Freedoms. The legislation was widely condemned, including by opposition parties, the Canadian Civil Liberties Association, Prime Minister Justin Trudeau, Minister of Justice and Attorney General of Canada David Lametti, the Ontario Bar Association, and other unions including those which had previously endorsed the PC Party. Despite the government's bill, CUPE went on strike anyway, resulting in province-wide school closures and protests in support of education workers. The government challenged CUPE at the Ontario Labour Relations Board. On November 7, 2022, Ford announced that he would rescind Bill 28 and that he would resume negotiations with CUPE. Following the strike, Ford said he did not regret his use of the notwithstanding clause in imposing the contract and said that it helped both sides "come to their senses". Following Paul Calandra's appointment as minister of education in 2025, he began appointing supervisors to take over several of Ontario's school boards. The government's Bill 33 would give the education ministry more power over school boards. In early 2026, Calandra announced the "Putting Student Achievement First Act," which includes many education reforms.
The study has enrolled over 20,000 newborns and expanded its panel to include 446 genes associated with more than 460 actionable conditions. The GUARDIAN study was recognized by JAMA as Research of the Year for 2025. Additionally, GeneDx is a partner in Florida's Sunshine Genetics Program, the first state-supported initiative to integrate genomic sequencing into newborn screening.
Sources: en.wikipedia.org
The sequence corresponds to a fragment of a protein found in human gastric juice, so related sequences are natural. The isolated fifteen-amino-acid peptide supplied for research is produced synthetically. Whether the free fragment circulates naturally in humans has not been settled.
In most jurisdictions it is not an approved medicine and is handled as a research material. Import and sale rules differ by country, and some regulators have placed it in categories that restrict human use. Status can change, so current local rules apply.
Rodent models dominate, particularly rats with induced gastric lesions, tendon injury, or vascular disruption. These designs allow controlled comparison but differ anatomically and metabolically from humans. Results from such models are commonly cited as preliminary.
Lyophilised peptide powders are generally kept frozen or refrigerated, dry, and protected from light. Sealed vials limit moisture uptake and slow hydrolysis. Such guidance comes from general peptide chemistry rather than from stability studies specific to every product.